Autoimmunity BioSolutions

Autoimmunity BioSolutions (ABS) is pioneering a next-generation immuno corrective therapy aimed at treating autoimmune diseases by targeting a novel pathway involving the soluble Interleukin 7 Receptor (sIL7R). The company focuses on a genetically defined subpopulation of patients whose autoimmune pathology is driven by a specific SNP that enhances sIL7R expression. ABS's therapy is being developed as a first-line treatment for various autoimmune diseases, specifically for patients identified by the presence of this SNP and elevated sIL7R levels. The business model revolves around delivering effective treatments that bypass traditional safety liabilities, addressing the unmet needs of patients requiring improved therapeutic options. ABS operates in the healthcare sector, particularly within the niche of autoimmune disease treatment, and generates revenue through the development and potential commercialization of its proprietary therapies.

Keywords: autoimmune, therapy, sIL7R, SNP, immune function, treatment, healthcare, patients, pathway, subpopulation.